Zoom Logo

MTI Seminar Series: Mike Romanos - Shared screen with speaker view
Milner Institute
22:35
Please add your questions here for Mike.
Janneke Ouwerkerk (NIZO)
52:52
I;
Jim Allpress
53:04
What are the challenges in translating from animal models to man?
Janneke Ouwerkerk (NIZO)
53:26
I'm really curious about your UC data, when do you expect that a product can be acually used as approved product for these patients?
Natalie Tigue
54:36
With respect to using bacteria as therapeutics, how often do you envisage having to dose, are there concerns re: the bacteria taking over the host microbiome and if so, are you employing "kill switches" as a safety mechanism?
Petar Scepanovic
57:15
Amazing work, thanks Mike! I have a question regarding your IP: could you elaborate a bit on your portfolio and, in general, patenting strategy?
Natalie Tigue
57:31
Are there efforts to understand the mechanisms by which the bacteria impart their effects? Could extracellular vesicles play a role, and provide an alternative modality?
Brian McGuinness
01:01:20
Hi Mike. Great talk, thanks. I may have missed it but how to do quality control your bank?
Paul Dupree
01:01:55
Do we understand gut microbiome ecology well enough to understand how and why some bacteria engraft? How active an area of research is this?
Rabab
01:02:17
What are your thoughts on the bacteria gene editing approach to alter the microbiome for therapeutic purposes?